Diego Martin-Sanchez1,2, Juan Guerrero-Mauvecin1, Miguel Fontecha-Barriuso1,2, Nerea Mendez-Barbero3,4, Maria Laura Saiz5, Ana M Lopez-Diaz1, Maria D Sanchez-Niño1,2,6, Susana Carrasco1, Pablo Cannata-Ortiz7, Marta Ruiz-Ortega1,2,8, Alberto Ortiz9,2,8,10, Ana B Sanz9,2. 1. Laboratorio de Nefrología Experimental, Instituto de Investigación Sanitaria-Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain. 2. Red de Investigacion Renal, Madrid, Spain. 3. Laboratorio de Patologia Vascular, Instituto de Investigación Sanitaria-Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain. 4. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain. 5. Translational Immunology Laboratory, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain. 6. Department of Pharmacology, Universidad Autonoma de Madrid, Madrid, Spain. 7. Department of Pathology, Instituto de Investigación Sanitaria-Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain. 8. Department of Medicine, Universidad Autonoma de Madrid, Madrid, Spain. 9. Laboratorio de Nefrología Experimental, Instituto de Investigación Sanitaria-Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain aortiz@fjd.es asanz@fjd.es. 10. Instituto Reina Sofia de Investigaciones Nefrologicas, Madrid, Spain.
Abstract
BACKGROUND: Receptor-interacting protein kinase 3 (RIPK3), a component of necroptosis pathways, may have an independent role in inflammation. It has been unclear which RIPK3-expressing cells are responsible for the anti-inflammatory effect of overall Ripk3 deficiency and whether Ripk3 deficiency protects against kidney inflammation occurring in the absence of tubular cell death. METHODS: We used chimeric mice with bone marrow from wild-type and Ripk3-knockout mice to explore RIPK3's contribution to kidney inflammation in the presence of folic acid-induced acute kidney injury AKI (FA-AKI) or absence of AKI and kidney cell death (as seen in systemic administration of the cytokine TNF-like weak inducer of apoptosis [TWEAK]). RESULTS: Tubular and interstitial cell RIPK3 expressions were increased in murine AKI. Ripk3 deficiency decreased NF-κB activation and kidney inflammation in FA-AKI but did not prevent kidney failure. In the chimeric mice, RIPK3-expressing bone marrow-derived cells were required for early inflammation in FA-AKI. The NLRP3 inflammasome was not involved in RIPK3's proinflammatory effect. Systemic TWEAK administration induced kidney inflammation in wild-type but not Ripk3-deficient mice. In cell cultures, TWEAK increased RIPK3 expression in bone marrow-derived macrophages and tubular cells. RIPK3 mediated TWEAK-induced NF-κB activation and inflammatory responses in bone marrow-derived macrophages and dendritic cells and in Jurkat T cells; however, in tubular cells, RIPK3 mediated only TWEAK-induced Il-6 expression. Furthermore, conditioned media from TWEAK-exposed wild-type macrophages, but not from Ripk3-deficient macrophages, promoted proinflammatory responses in cultured tubular cells. CONCLUSIONS: RIPK3 mediates kidney inflammation independently from tubular cell death. Specific targeting of bone marrow-derived RIPK3 may limit kidney inflammation without the potential adverse effects of systemic RIPK3 targeting.
BACKGROUND: Receptor-interacting protein kinase 3 (RIPK3), a component of necroptosis pathways, may have an independent role in inflammation. It has been unclear which RIPK3-expressing cells are responsible for the anti-inflammatory effect of overall Ripk3 deficiency and whether Ripk3 deficiency protects against kidney inflammation occurring in the absence of tubular cell death. METHODS: We used chimeric mice with bone marrow from wild-type and Ripk3-knockout mice to explore RIPK3's contribution to kidney inflammation in the presence of folic acid-induced acute kidney injury AKI (FA-AKI) or absence of AKI and kidney cell death (as seen in systemic administration of the cytokine TNF-like weak inducer of apoptosis [TWEAK]). RESULTS: Tubular and interstitial cell RIPK3 expressions were increased in murine AKI. Ripk3 deficiency decreased NF-κB activation and kidney inflammation in FA-AKI but did not prevent kidney failure. In the chimeric mice, RIPK3-expressing bone marrow-derived cells were required for early inflammation in FA-AKI. The NLRP3 inflammasome was not involved in RIPK3's proinflammatory effect. Systemic TWEAK administration induced kidney inflammation in wild-type but not Ripk3-deficient mice. In cell cultures, TWEAK increased RIPK3 expression in bone marrow-derived macrophages and tubular cells. RIPK3 mediated TWEAK-induced NF-κB activation and inflammatory responses in bone marrow-derived macrophages and dendritic cells and in Jurkat T cells; however, in tubular cells, RIPK3 mediated only TWEAK-induced Il-6 expression. Furthermore, conditioned media from TWEAK-exposed wild-type macrophages, but not from Ripk3-deficient macrophages, promoted proinflammatory responses in cultured tubular cells. CONCLUSIONS: RIPK3 mediates kidney inflammation independently from tubular cell death. Specific targeting of bone marrow-derived RIPK3 may limit kidney inflammation without the potential adverse effects of systemic RIPK3 targeting.
Authors: Angara Sureshbabu; Edwin Patino; Kevin C Ma; Kristian Laursen; Eli J Finkelsztein; Oleh Akchurin; Thangamani Muthukumar; Stefan W Ryter; Lorraine Gudas; Augustine M K Choi; Mary E Choi Journal: JCI Insight Date: 2018-06-07
Authors: Kate E Lawlor; Rebecca Feltham; Monica Yabal; Stephanie A Conos; Kaiwen W Chen; Stephanie Ziehe; Carina Graß; Yifan Zhan; Tan A Nguyen; Cathrine Hall; Angelina J Vince; Simon M Chatfield; Damian B D'Silva; Kenneth C Pang; Kate Schroder; John Silke; David L Vaux; Philipp J Jost; James E Vince Journal: Cell Rep Date: 2017-07-18 Impact factor: 9.423
Authors: Diego Martin-Sanchez; Miguel Fontecha-Barriuso; Susana Carrasco; Maria Dolores Sanchez-Niño; Anne von Mässenhausen; Andreas Linkermann; Pablo Cannata-Ortiz; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz; Ana Belen Sanz Journal: Proc Natl Acad Sci U S A Date: 2018-03-27 Impact factor: 11.205
Authors: Kate E Lawlor; Nufail Khan; Alison Mildenhall; Motti Gerlic; Ben A Croker; Akshay A D'Cruz; Cathrine Hall; Sukhdeep Kaur Spall; Holly Anderton; Seth L Masters; Maryam Rashidi; Ian P Wicks; Warren S Alexander; Yasuhiro Mitsuuchi; Christopher A Benetatos; Stephen M Condon; W Wei-Lynn Wong; John Silke; David L Vaux; James E Vince Journal: Nat Commun Date: 2015-02-18 Impact factor: 14.919
Authors: Julio M Martinez-Moreno; Miguel Fontecha-Barriuso; Diego Martín-Sánchez; Maria D Sánchez-Niño; Marta Ruiz-Ortega; Ana B Sanz; Alberto Ortiz Journal: Front Pharmacol Date: 2020-04-03 Impact factor: 5.810